<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Selective cyclooxygenase-2 (COX2) inhibitors are widely used as <z:chebi fb="29" ids="35480">analgesics</z:chebi> and it is unclear whether its long-term use affects <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A series of nested case-control studies using the QResearch primary care database </plain></SENT>
<SENT sid="2" pm="."><plain>Associations of COX2 inhibitor use with risk of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and 10 common site-specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were estimated using conditional logistic regression adjusted for comorbidities, smoking status, socioeconomic status, and use of <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi>, aspirin and <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A total of 88,125 cancers, diagnosed between 1998 and 2008, matched with up to five controls, were analysed </plain></SENT>
<SENT sid="4" pm="."><plain>Use of COX2 inhibitors for more than a year was associated with a significantly increased risk of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (odds ratio (OR) 1.24, 95% confidence interval (CI) 1.08-1.42) and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> (OR 1.38, 95% CI 1.12-1.69) and a decreased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (OR 0.76, 95% CI 0.63-0.92) </plain></SENT>
<SENT sid="5" pm="."><plain>There were no other significant associations </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Prolonged use of COX2 inhibitors was associated with an increased risk of breast and haematological <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and decreased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>These findings need to be confirmed using other data sources </plain></SENT>
</text></document>